Compare Levi Strauss & Co. (LEVI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs TG Therapeutics Inc — how do they compare? Levi Strauss & Co. trades at $22.8 (market cap $8.75B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Levi Strauss & Co. and TG Therapeutics Inc are close in size by market cap, and Levi Strauss & Co. pays a 2.81% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LEVI | TGTX | |
|---|---|---|
Market Cap | $8.75B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $59.06 |
52-Week Low | $17.92 | $26.94 |
Enterprise Value | $10.07B | $7.84B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $22.47, down 4.75% today, but maintains strong fundamentals with a P/E of 16.24 and robust profitability metrics including 61.72% gross margin and 29.31% ROE. The company has beaten earnings estimates for three consecutive quarters and recently raised its dividend. Technical indicators show mixed signals with bearish moving averages but oversold RSI conditions, while analyst consensus remains strongly bullish with a $27.88 price target.
LEVI presents a compelling value opportunity with consistent earnings outperformance and digital transformation progress, though recent cybersecurity concerns and tariff pressures create near-term headwinds. The stock's current valuation discount to analyst targets and strong DTC growth strategy support upside potential, but investors should monitor execution risks and market volatility.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
